Skip to main content

Table 4 Susceptibility patterns for selected antibiotic substances and pathogens per year

From: The epidemiology of bloodstream infections and antimicrobial susceptibility patterns in Thuringia, Germany: a five-year prospective, state-wide surveillance study (AlertsNet)

  2015 2016 2017 2018 2019 OR (95% CI)
p value
Escherichia coli
Aminopenicillin 941/486
(51.6)
1,282/711
(55.5)
1,426/785
(55.0)
1,595/920
(57.7)
1,536/940
(61.2)
1.06 (1.02; 1.10) 0.006
Fluoroquinolones 941/221
(23.5)
1,286/315
(24.5)
1,441/367
(25.5)
1,600/438
(27.4)
1,567/384
(24.5)
1.01 (0.97; 1.05) 0.72
Cefotaxime 938/100
(10.7)
973/134
(13.8)
912/122
(13.4)
1,228/178
(14.5)
1,355/197
(14.5)
1.08 (1.02; 1.14). 0.007
Carbapenems 941/1
(0.1)
1,286/3
(0.2)
1,441/3
(0.2)
1,600/0
(0.0)
1,538/1
(0.1)
6
Aminoglycosides 941/57
(6.1)
1,286/122
(9.5)
1,473/143
(9.7)
1,594/151
(9.5)
1,535/280
(18.2)2
1.30 (1.21; 1.40) < 0.001
Fosfomycin 339/1
(0.4)
562/6
(1.1)
630/6
(1.0)
637/9
(1.4)
518/7
(1.4)
6
Trimethoprim-sulfamethoxazole 941/293
(31.1)
1281/408
(31.9)
1435/439
(30.6)
1593/444
(27.9)
1533 /403
(26.3)
0.93 (0.89; 0.97) < 0.001
Klebsiella pneumoniae
Fluoroquinolones 181/25
(13.8)
232/38
(16.4)
227/40
(17.6)
254/49
(19.3)
270/36
(13.3)
1.02 (0.91; 1.15) 0.72
Cefotaxime 181/18
(9.9)
197/26
(13.3)
154/21
(13.6)
202/24
(11.9)
242/18
(7.4)
0.93 (0.81; 1.08) 0.35
Carbapenems 181/2
(1.1)
232/0
(0.0)
227/0
(0.0)
254/2
(0.8)
270/2
(0.7)
6
Aminoglycosides 181/7
(3.9)
232/12
(5.2)
227/14
(6.2)
253/18
(7.1)
270/33
(12.2)2
1.47 (1.19; 1.82) < 0.001
Fosfomycin 54/6
(11.1)
117/19
(16.2)
113/15
(13.3)
115/16
(13.9)
92/12
(13.0)
1.01 (0.82; 1.24) 0.95
Trimethoprim-sulfamethoxazole 181/22
(12.2)
231/34
(14.7)
227/33
(14.5)
253/33
(13.0)
270/39
(14.4)
1.06 (0.88; 1.26) 0.56
Pseudomonas aeruginosa
Fluoroquinolones 48/10
(16.3)
72/15
(18.1)
87/23
(16.5)
120/19
(13.5)
5 1.21 (0.97; 1.51) 0.09
Ceftazidime 47/3
(4.8)
72/3
(2.8)
85/7
(7.2)
127/6
(4.0)
5 2.14 (1.29; 3.54) 0.003
Piperacillin/Tazobactam 46/7
(12.2)
71/4
(5.6)
85/9
(9.5)
131/19
(14.1)
5 1.30 (0.97; 1.74) 0.07
Carbapenems 46/4
(9.8)
72/10
(13.9)
88/17
(17.4)
131/17
(11.7)
5 1.17 (0.92; 1.49) 0.20
Aminoglycosides 47/6
(11.9)
72/4
(2.8)
88/8
(7.0)
129/3
(1.6)
5 1.03 (0.72; 1.47) 0.88
Combined resistance3 46/5
(10.9)
71/3
(4.2)
87/8
(9.2)
127/7
(5.5)
5 6
Acinetobacter spp.     5  
Fluoroquinolones 27/5
(18.5)
33/6
(18.2)
35/11
(31.4)
32/8
(25.0)
5 6
Carbapenems 27/0
(0.0)
33/1
(3.0)
35/3
(8.6)
33/1
(3.0)
5 6
Aminoglycosides 27/1
(3.7)
33/0
(0.0)
33/3
(9.1)
32/1
(3.1)
5 6
Combined resistance4 27/0
(0.0)
33/0
(0.0)
33/2
(6.1)
32/1
(3.1)
5 6
  1. Number of tested isolates/number of resistant1 isolates (% resistant). The right column displays the results from the logistic regression with GEE as odds ratio (OR) for resistance for the unadjusted linear predictor year (i.e. OR per year) with 95% confidence interval (95% CI) and corresponding two-sided p-value
  2. 1Resistant and intermediate isolates; number of tested pathogens per year and antimicrobial substance can vary as not always antimicrobial testing for each substance was performed in each isolate, 2increase of resistance most probably due to new EUCAST MIC breakpoints, 3Combined resistance of at least 3 out of 5 antibiotics under surveillance, 4Resistent to all tested antibiotics under surveillance, 5not reported due to change in EUCAST methodology, 6not evaluated due to the small numbers of event